Gene polymorphisms of CYP2C19,MTHFR,SLCO1B1 and APOE in acute cerebral infarction patients
10.3969/j.issn.1673-4130.2024.01.020
- VernacularTitle:急性脑梗死患者CYP2C19、MTHFR、SLCO1B1和APOE基因检测结果分析
- Author:
Fuxiu HUANG
1
;
Dongqing ZHANG
Author Information
1. 中国人民解放军总医院第四医学中心消化内科,北京 100048
- Keywords:
acute cerebral infarction;
CYP2C19;
MTHFR;
SLCO1B1;
APOE;
genetic polymor-phism
- From:
International Journal of Laboratory Medicine
2024;45(1):104-108
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the distribution of CYP2C19,MTHFR,SLCO1B1,and APOE gene poly-morphisms in patients with acute cerebral infarction,so as to provide theoretical basis for individualized drug treatment.Methods A total of 400 patients with acute cerebral infarction admitted to the hospital from 2020 to 2022 were selected as the research subjects,and the polymorphisms of CYP2C19,MTHFR,SLCO1B1 and APOE genes were tested by PCR fluorescene probe method,and the polymorphism distribution of those genes was analyzed.Results In patients with acute cerebral infarction,44.25％of CYP2C19 gene phenotype were EM type,and 9.75％of CYP2C19 gene phenotype were PM type.The proportion of mutations at the C677T locus of the MTHFR gene(CT type+TT type)was 78.50％,CC type accounted for 21.50％.78.75％of the SLCO1B1 genotypes were type Ⅰ wild type,and 1.50％SLCO1B1 gene phenotypes were type Ⅲ homozygous mutant type.The E2 and E3 types accounted for 84.25％of the APOE gene phenotype,while the E4 type ac-counted for 15.75％.Conclusion The distribution of CYP2C19,MTHFR,SLCO1B1 and APOE gene poly-morphisms in 400 acute cerebral infarction patients is analyzed,providing data support for guiding individual-ized medication in the population of acute cerebral infarction patients and of great significance for achieving safe medication.
